STAT+: Pharmalittle: We’re reading about an FDA commissioner candidate, Germany’s plans for drug prices, and more

🇺🇸 STAT News Health (US) —
STAT+: Pharmalittle: We’re reading about an FDA commissioner candidate, Germany’s plans for drug prices, and more

AI Summary

Regenxbio is preparing to seek accelerated FDA approval for its gene therapy targeting Duchenne muscular dystrophy in the United States. The news includes discussion of an FDA commissioner candidate and Germany's drug pricing strategies.

Regenxbio plans to apply for accelerated approval for its gene therapy for Duchenne muscular dystrophy.

Politics Health FDA gene therapy Duchenne muscular dystrophy accelerated approval drug pricing Regenxbio health policy

Read original source →